Protalix BioTherapeutics (PLX) Total Non-Current Liabilities (2010 - 2026)

Protalix BioTherapeutics has reported Total Non-Current Liabilities for 17 years, with the latest figure at $7.5 million in Q2 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 67.88% year-over-year to $7.5 million in Q2 2026; TTM through Jun 2026 was $7.5 million, a 67.88% increase from a year earlier, with the FY2025 full-year figure at $7.6 million, up 65.71% from the prior year.
• Total Non-Current Liabilities was $7.5 million for Q2 2026 at Protalix BioTherapeutics, down from $7.7 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $40.5 million in Q1 2022, with the low at $4.4 million in Q1 2025.
• Average Total Non-Current Liabilities over 5 years is $15.5 million, with a median of $7.5 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities surged 445.93% in 2022, then slumped 84.69% in 2024.
• Over 5 years, Total Non-Current Liabilities stood at $34.0 million in 2022, then sank by 84.31% to $5.3 million in 2023, then declined by 14.06% to $4.6 million in 2024, then soared by 65.71% to $7.6 million in 2025, then decreased by 0.75% to $7.5 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $7.5 million (Q2 2026), $7.7 million (Q1 2026), and $7.6 million (Q4 2025), per Business Quant data.